Jiangsu wuzhong(SH:600200) Shang Hai Zheng Quan Bao·2025-09-24 21:28Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. is currently involved in an arbitration case with Regen Biotech, Inc. regarding a distribution contract dispute, which has significant implications for the company's financial performance and operational capabilities [2][3][4]. Arbitration Basic Situation - The company's subsidiary, Datuo Medical, initiated arbitration against Regen Biotech for breach of contract, seeking to confirm the validity of the exclusive agency agreement and claiming preliminary damages of RMB 1.6 billion [3]. - The arbitration case was accepted by the Shenzhen International Arbitration Court on August 7, 2025, with the case number (2025) Shen Guo Zhong She Wai 8781 [3]. - On September 10, 2025, the court issued a decision regarding emergency measures requested by Datuo Medical [3]. Arbitration Progress - On September 23, 2025, the arbitration court accepted a counterclaim from Regen Biotech regarding the distribution contract dispute [4]. Counterclaim Main Content - The counterclaim includes requests to terminate Datuo Medical's exclusive agency rights for AestheFill products in mainland China, confirm the termination of related agreements, and seek compensation for reasonable expenses incurred by Regen Biotech [5]. Impact on the Company - The arbitration has not yet been heard, and the final outcome remains uncertain, which will directly affect the company's profits in the current and future periods [6]. - As of now, Regen Biotech has not complied with the court's emergency decision, hindering Datuo Medical's ability to sell AestheFill products [7].